Treatment with obeticholic acid (an FXR agonist) has been tested in NASH (a severe form of NAFLD)—it did improve liver histology in some patients but with side effects [133]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.